The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global rapid acting insulin market reached a value of US$ XX Billion in 2021. Looking forward, IMARC Group expects the market to grow at a CAGR of XX% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Rapid acting insulin is a medication used to control glucose levels in patients with diabetes. It is either inhaled or administered into the bloodstream with a syringe, a pre-filled pen, or an insulin pump. It is taken prior to meals and snacks to bring overly high blood glucose to a normal level and surge the level of bolus insulin. At present, new insulin formulations like novel ultra-paid-acting insulins that enhance absorption are considered a suitable option for people who cannot achieve postprandial glycemic targets with other bolus insulins.
Diabetes mellitus (DM) and poorly controlled blood glucose can increase the risk of mortality and severity among patients with coronavirus disease (COVID-19). This represents one of the key factors fueling the need for rapid acting insulins to monitor blood glucose levels. Apart from this, the growing prevalence of type 1 diabetes on account of exposure to viruses and other environmental factors and low levels of vitamin D acts as another factor propelling the demand for rapid acting insulins across the globe. This can also be attributed to the increasing instances of neonatal jaundice in newborns, in confluence with improving diagnostic modalities. In addition to this, as the risk of developing diabetes increases with age, the rising global geriatric population is facilitating the market growth. Furthermore, leading market players are introducing ready-to-use rapid acting insulin kits that are fast, accessible in vials and a pen presentation, and help enhance glycemic control in both adults and children. These players are also focusing on mergers and acquisitions (M&A), which is anticipated to contribute to the development of new-generation product variants.
IMARC Group provides an analysis of the key trends in each sub-segment of the global rapid acting insulin market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product, indication and distribution channel.
Breakup by Product:
Breakup by Indication:
Breakup by Distribution Channel:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Adocia, Biocon Limited, Eli Lilly and Company, Gan & Lee Pharmaceuticals Co. Ltd., Geropharm, MannKind Corporation, Merck & Co. Inc., Novo Nordisk A/S, Sanofi S.A., and Wockhardt Ltd.
|Base Year of the Analysis||2021|
|Segment Coverage||Product, Indication, Distribution Channel, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Adocia, Biocon Limited, Eli Lilly and Company, Gan & Lee Pharmaceuticals Co. Ltd., Geropharm, MannKind Corporation, Merck & Co. Inc., Novo Nordisk A/S, Sanofi S.A., and Wockhardt Ltd.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at